← Back to patent-cliff list
Celecoxib
Tier B — Position earlyCelecoxib
Pfizer Inc.
Originator
1998
First approval
-
Expiry (public)
$3.33B ▲
Peak sales
Small molecule
Type
Targets：COX-2
Brand：Vyscoxa, Celebrex, Nu-Celecoxib, Celebra, Onsenal, Celecox, Solexa
Indications (approved)：Pain, Inflammatory disease, 关节周围炎, 肌腱炎, 颈肩腕综合征, Low back pain, Osteoarthritis, Rheumatoid arthritis
Regional status
US
Approved
1998-12-31
EU
Withdrawn
China
Approved
2000-08-04
Japan
Approved
2007-01-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Celecoxib?
Approved indications include: Pain, Inflammatory disease, 关节周围炎, 肌腱炎, 颈肩腕综合征, Low back pain, Osteoarthritis, Rheumatoid arthritis.
When does the Celecoxib patent expire?
No public expiry year is available for Celecoxib yet; this page updates once verified.
How do I get a quote for Celecoxib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27